Company intelligence / Profile preview

Rannis

San Jose, California, United Statesen.rannis.is ↗

Ownership: Private
Employees: ~106
Development stage: Other

Overview

The company has demonstrated high reliability and safety/tolerability in humans for its oral biologic delivery technology. Its lead program is in Phase I for osteoporosis. Other assets are at preclinical or discovery stages targeting autoimmune/inflammatory diseases and metabolic disorders. The technology shows bioavailability comparable to or better than subcutaneous injections in early studies

Therapeutic areas: RheumatologyImmunologyEndocrinology
Modalities: Small moleculePeptidesProteinsAntibodyOligonucleotide
Industry: Biotech

Partnerships

ProGen Co., Ltd. for co-development/commercialization of obesity candidateChugai Pharmaceutical research agreement

Beyond the preview

Go deeper on Rannis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rannis.

Explore the full profile